



MEN

FIRST CANCER SITE
STOMACHSTOMACH
POOL AIRTUM 1976-2010, MEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

STOMACO
POOL AIRTUM 1976-2010, UOMINI:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months
No. of subjects alive at interval beginning ▶	42022		53697		53697		42022		23028		7538		3090		42022	53697
Person-years ▶	114047		121984		7937		25320		50209		24897		13621		114047	121984
SECOND CANCER SITE	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR
ALL SITES, BUT SKIN AND STOMACH	2291	0.97	3144	1.25	853	5.26	358	0.71	1059	1.05	558	1.04	316	1.00	-0.61	5.09
HEAD AND NECK	95	0.96	125	1.18	30	4.23	16	0.72	38	0.87	28	1.32	13	1.12	-0.03	0.16
ORAL CAVITY	17	0.74	28	1.14	11	6.81	2	0.39	7	0.70	7	1.40	1	0.36	-0.05	0.03
PHARYNX	22	1.10	26	1.21	4	2.83	6	1.33	7	0.79	8	1.86	1	0.42	0.02	0.04
LARYNX	56	1.00	71	1.19	15	3.69	8	0.63	24	0.97	13	1.09	11	1.71	0.00	0.09
OESOPHAGUS	38	1.44	78	2.77	40	20.97	7	1.19	18	1.58	8	1.39	5	1.53	0.10	0.41
STOMACH	2	0.01	18	0.10	16	1.23	2	0.05	0	0.00	0	0.00	0	0.00	-1.46	-1.34
COLON RECTUM	356	1.02	586	1.57	230	9.58	54	0.73	173	1.17	81	1.01	48	1.00	0.06	1.74
COLON	232	0.97	413	1.62	181	11.16	30	0.60	115	1.14	52	0.94	35	1.05	-0.06	1.29
RECTUM	124	1.12	173	1.46	49	6.29	24	1.00	58	1.23	29	1.16	13	0.90	0.12	0.45
LIVER	67	0.69	116	1.12	49	7.39	12	0.58	35	0.84	11	0.50	9	0.70	-0.26	0.10
GALLBLADDER	30	1.08	36	1.21	6	3.05	5	0.84	15	1.28	6	0.95	4	1.06	0.02	0.05
PANCREAS	108	1.58	121	1.66	13	2.75	12	0.83	53	1.83	30	1.92	13	1.39	0.35	0.39
LUNG	393	0.89	518	1.09	125	3.98	58	0.60	170	0.89	101	1.03	64	1.14	-0.44	0.36
SKIN MELANOMA	38	1.17	42	1.22	4	1.98	10	1.54	12	0.88	11	1.45	5	1.06	0.05	0.06
MESOTHELIOMA	7	0.57	9	0.69	2	2.56	0	0.00	1	0.19	2	0.70	4	2.27	-0.05	-0.03
KAPOSI SARCOMA	2	0.39	3	0.55	1	2.74	0	0.00	2	0.92	0	0.00	0	0.00	-0.03	-0.02
SOFT TISSUE	11	1.30	12	1.33	1	1.74	1	0.56	6	1.67	4	2.07	0	0.00	0.02	0.02
BONE	3	1.34	3	1.24	0	0.00	0	0.00	2	2.04	0	0.00	1	3.72	0.01	0.00
BREAST	9	1.69	9	1.58	0	0.00	2	1.77	4	1.78	2	1.65	1	1.39	0.03	0.03
PROSTATE	438	0.90	521	1.00	83	2.60	57	0.58	204	1.00	121	1.06	56	0.80	-0.43	0.02
TESTIS	6	2.42	7	2.64	1	5.74	2	3.54	3	2.69	1	1.90	0	0.00	0.03	0.04
KIDNEY AND RENAL PELVIS	71	0.94	138	1.71	67	13.33	15	0.95	36	1.11	14	0.81	6	0.59	-0.04	0.47
BLADDER AND URINARY TRACT	331	1.17	386	1.28	55	2.81	60	1.00	160	1.33	60	0.94	51	1.36	0.43	0.69
URINARY BLADDER	320	1.19	372	1.29	52	2.77	59	1.02	154	1.34	58	0.95	49	1.37	0.45	0.69
URINARY TRACT	11	0.88	14	1.04	3	3.46	1	0.38	6	1.13	2	0.69	2	1.16	-0.01	0.00
BRAIN AND CENTRAL NERVOUS SYSTEM	19	0.70	20	0.69	1	0.54	4	0.69	7	0.60	6	0.99	2	0.58	-0.07	-0.07
THYROID	11	1.13	12	1.16	1	1.62	0	0.00	8	1.90	3	1.35	0	0.00	0.01	0.01
HODGKIN LYMPHOMA	0	0.00	4	0.80	4	11.68	0	0.00	0	0.00	0	0.00	0	0.00	-0.04	-0.01
NON-HODGKIN LYMPHOMA	72	1.05	138	1.88	66	14.24	13	0.90	34	1.16	15	0.95	10	1.08	0.03	0.53
MYELOMA	31	0.92	36	1.00	5	2.10	6	0.83	10	0.70	11	1.43	4	0.88	-0.02	0.00
LEUKAEMIAS	75	1.28	107	1.70	32	7.58	11	0.86	33	1.32	23	1.73	8	1.04	0.14	0.36
LYMPHOID LEUKAEMIAS	27	0.97	47	1.57	20	9.97	5	0.82	10	0.84	9	1.43	3	0.84	-0.01	0.14
MYELOID LEUKAEMIAS	41	1.56	52	1.85	11	5.94	5	0.89	18	1.62	14	2.33	4	1.13	0.13	0.20
OTHER LEUKAEMIAS	7	1.54	8	1.63	1	2.76	1	0.95	5	2.58	0	0.00	1	1.83	0.02	0.03
OTHER AND ILL DEFINED SITES	80	0.60	117	0.82	37	3.92	13	0.46	35	0.62	20	0.65	12	0.65	-0.47	-0.22

Decrease/Difetto
Increase/Eccesso

Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio



WOMEN

FIRST CANCER SITE
STOMACHSTOMACH
POOL AIRTUM 1976-2010, WOMEN:

Number of subjects alive at the beginning of the interval, person-years at risk (PY), number of Observed (O) second cancers, Standardized Incidence Ratio (SIR) and Excess Absolute Risk (EAR) x 1000 cancer patients by second cancer site and follow-up period.

STOMACH
POOL AIRTUM 1976-2010, DONNE:

Numero di soggetti vivi all'inizio dell'intervallo, anni persona a rischio (PY), numero di secondi tumori osservati (O), rapporto standardizzato di incidenza (SIR) ed eccesso assoluto di rischio (EAR) x 1000 pazienti per sede di secondo tumore e periodo di follow-up.

months after first cancer ▶	≥2 months		≥0 months		0-1 months		2-11 months		12-59 months		60-119 months		≥120 months		≥2 months	≥0 months		
	No. of subjects alive at interval beginning ▶	Person-years ▶	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR		
SECOND CANCER SITE			O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	O	SIR	EAR	EAR		
ALL SITES, BUT SKIN AND STOMACH	1044	93325	1044	0.94	1478	1.25	434	6.35	177	0.82	462	0.99	261	0.97	144	0.89	-0.76	2.98
HEAD AND NECK	15	7	15	1.03	18	1.17	3	3.36	3	1.06	6	0.98	3	0.86	3	1.43	0.01	0.03
ORAL CAVITY	7	7	7	0.85	8	0.92	1	2.00	2	1.28	3	0.88	2	1.00	0	0.00	-0.01	-0.01
PHARYNX	5	5	5	1.71	6	1.93	1	5.50	0	0.00	3	2.39	0	0.00	2	5.10	0.02	0.03
LARYNX	3	3	3	0.88	4	1.11	1	4.76	1	1.48	0	0.00	1	1.25	1	2.14	0.00	0.00
OESOPHAGUS	7	7	7	1.08	16	2.32	9	21.33	1	0.78	6	2.23	0	0.00	0	0.00	0.01	0.09
STOMACH	5	5	5	0.06	15	0.16	10	1.64	3	0.16	1	0.03	1	0.05	0	0.00	-0.88	-0.79
COLON RECTUM	210	210	210	1.06	341	1.62	131	10.51	25	0.65	106	1.28	62	1.28	17	0.58	0.12	1.31
COLON	160	160	160	1.12	264	1.74	104	11.63	18	0.65	86	1.45	43	1.23	13	0.61	0.18	1.13
RECTUM	50	50	50	0.90	77	1.31	27	7.66	7	0.64	20	0.86	19	1.42	4	0.51	-0.06	0.18
LIVER	16	16	16	0.47	25	0.70	9	4.25	4	0.61	7	0.50	3	0.37	2	0.40	-0.19	-0.11
GALLBLADDER	21	21	21	0.73	31	1.01	10	5.34	3	0.53	8	0.67	7	1.01	3	0.72	-0.08	0.00
PANCREAS	85	85	85	1.61	92	1.65	7	2.17	9	0.91	41	1.91	21	1.61	14	1.70	0.35	0.36
LUNG	57	57	57	0.76	74	0.94	17	3.87	3	0.21	23	0.75	15	0.82	16	1.40	-0.19	-0.05
SKIN MELANOMA	13	13	13	0.67	15	0.73	2	1.77	1	0.27	8	0.98	3	0.64	1	0.35	-0.07	-0.06
MESOTHELIOMA	2	2	2	0.69	3	0.98	1	6.05	0	0.00	0	0.00	1	1.40	1	2.19	-0.01	0.00
KAPOSI SARCOMA	1	1	1	0.58	2	1.08	1	8.98	0	0.00	1	1.40	0	0.00	0	0.00	-0.01	0.00
SOFT TISSUE	5	5	5	1.04	6	1.18	1	3.45	2	2.17	1	0.50	2	1.72	0	0.00	0.00	0.01
BONE	1	1	1	0.75	1	0.70	0	0.00	0	0.00	1	1.76	0	0.00	0	0.00	0.00	0.00
BREAST	254	254	254	0.94	332	1.16	78	4.81	58	1.11	97	0.85	60	0.93	39	1.02	-0.17	0.46
CERVIX UTERI	14	14	14	0.97	15	0.98	1	1.04	4	1.31	6	0.95	4	1.23	0	0.00	0.00	0.00
CORPUS UTERI	48	48	48	0.99	54	1.05	6	2.05	4	0.42	27	1.30	8	0.70	9	1.37	0.00	0.03
OVARY	44	44	44	1.24	60	1.59	16	7.31	6	0.86	22	1.46	9	1.06	7	1.41	0.09	0.23
KIDNEY AND RENAL PELVIS	26	26	26	0.93	63	2.12	37	22.43	8	1.52	9	0.77	5	0.73	4	0.95	-0.02	0.34
BLADDER AND URINARY TRACT	51	51	51	1.05	61	1.19	10	3.34	15	1.62	16	0.80	13	1.10	7	0.96	0.03	0.10
URINARY BLADDER	49	49	49	1.09	57	1.20	8	2.88	14	1.63	16	0.86	12	1.09	7	1.04	0.04	0.09
URINARY TRACT	2	2	2	0.56	4	1.06	2	9.35	1	1.52	0	0.00	1	1.13	0	0.00	-0.02	0.00
BRAIN AND CENTRAL NERVOUS SYSTEM	11	11	11	0.67	13	0.75	2	2.05	0	0.00	5	0.73	4	1.01	2	0.84	-0.06	-0.04
THYROID	16	16	16	1.03	18	1.10	2	2.31	2	0.68	9	1.35	5	1.34	0	0.00	0.01	0.02
HODGKIN LYMPHOMA	1	1	1	0.39	1	0.36	0	0.00	0	0.00	1	0.89	0	0.00	0	0.00	-0.02	-0.02
NON-HODGKIN LYMPHOMA	36	36	36	0.83	76	1.65	40	15.33	8	0.96	18	0.99	7	0.66	3	0.47	-0.08	0.30
MYELOMA	14	14	14	0.65	25	1.09	11	8.16	4	0.95	5	0.55	2	0.38	3	0.96	-0.08	0.02
LEUKAEMIAS	30	30	30	0.94	45	1.33	15	7.42	5	0.80	18	1.36	4	0.52	3	0.65	-0.02	0.11
LYMPHOID LEUKAEMIAS	9	9	9	0.64	22	1.46	13	14.25	2	0.71	5	0.85	1	0.29	1	0.50	-0.06	0.07
MYELOID LEUKAEMIAS	20	20	20	1.37	21	1.35	1	1.10	3	1.07	12	1.98	3	0.84	2	0.92	0.06	0.06
OTHER LEUKAEMIAS	1	1	1	0.33	2	0.61	1	4.92	0	0.00	1	0.79	0	0.00	0	0.00	-0.02	-0.01
OTHER AND ILL DEFINED SITES	66	66	66	0.67	91	0.86	25	4.00	12	0.63	21	0.52	23	0.94	10	0.66	-0.35	-0.14

Decrease/Difetto
Increase/Eccesso

O Observed cases
Casi osservati

SIR Standardized Incidence Ratio
Rapporto standardizzato di incidenza

EAR Excess Absolute Risk
Eccesso assoluto di rischio